Low-dose formulation of PremPro hormone replacement therapy is "approvable" at FDA for treatment of vasomotor symptoms, AHP Chief Operating Officer Robert Essner says. "The idea that you can get the benefits of HRT now at a substantially lower dose, we think is the kind of momentum that we need to get the category back and the product back on a much more positive track." Approval of low-dose PremPro (conjugated estrogens/medroxyprogesterone acetate combo) is expected in the second half
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth